Back to top
more

AbbVie (ABBV)

(Delayed Data from NYSE)

$198.05 USD

198.05
4,101,681

-0.81 (-0.41%)

Updated Aug 8, 2025 04:00 PM ET

After-Market: $198.10 +0.05 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (68 out of 244)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

North Chicago, IL-based AbbVie has become one of the top-most pharma companies after it acquired Botox maker Allergan in a cash-and-stock deal for $63 billion in May 2020. The deal is expected to transform AbbVie’s portfolio and lower its dependence on Humira, its flagship product, which has already lost patent protection in Europe and is due to face biosimilar competition in the United States in 2023. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest drugs Skyrizi (risankizumab) and Rinvoq (upadacitinib) position it well for long-term growth.

Zacks Equity Research

AbbVie (ABBV) Up 6.9% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

AbbVie (ABBV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Reata's (RETA) Q4 Earnings Miss Mark, Revenues Decline Y/Y

by Zacks Equity Research

Reata (RETA) reports a wider-than-expected loss in the fourth quarter of 2021 while revenues are slightly lower than estimates.

Kinjel Shah headshot

Pharma Stock Roundup: GSK, SNY Face Pipeline Setbacks, AZN Cancer Study Meets Goals

by Kinjel Shah

Glaxo (GSK) and Sanofi (SNY) announce pipeline setbacks. AstraZeneca's (AZN) HER2-low metastatic breast cancer study on Enhertu succeeds.

Zacks Equity Research

Viatris (VTRS) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Viatris' (VTRS) Q4 earnings might have gained from the solid performance of Lipitor, Influvac, Viagra and EpiPen.

Zacks Equity Research

Ironwood (IRWD) Q4 Earnings Miss, Linzess Volume Grows

by Zacks Equity Research

Ironwood (IRWD) witnesses flat year-over-year sales growth. Its fourth-quarter earnings miss estimates. The company maintains revenue guidance for 2022. Stock declines.

Zacks Equity Research

Zacks Value Trader Highlights: Mastercard, Visa, Chevron and AbbVie

by Zacks Equity Research

Mastercard, Visa, Chevron and AbbVie are highlighted in this Value Trader article.

Tracey Ryniec headshot

Who's Really Making the Berkshire Hathaway Stock Trades?

by Tracey Ryniec

It used to be Warren Buffett making all the portfolio decisions, but it's pretty obvious those days are over.

Zacks Equity Research

Biohaven (BHVN) Migraine Drug Meets Study Goals in China

by Zacks Equity Research

Biohaven (BHVN) and partner Pfizer announce positive top-line results from a phase III study on rimegepant for the acute treatment of migraine. The study meets the co-primary endpoints.

Zacks Equity Research

Zacks Industry Outlook Highlights: Sanofi, AbbVie, Bristol-Myers, Amgen and Vertex Pharmaceuticals

by Zacks Equity Research

Sanofi, AbbVie, Bristol-Myers, Amgen and Vertex Pharmaceuticals are highlighted in this Industry Outlook article.

Zacks Equity Research

Will the Rally of These 5 Big Drugmakers Continue in 2022?

by Zacks Equity Research

Here we discuss five big pharma/biotech companies - SNY, ABBV, BMY, AMGN and VRTX - with the potential to drive investors' wealth higher in 2022 on the back of strong fundamentals.

Zacks Equity Research

The Zacks Analyst Blog Highlights AbbVie, The Boeing Company, Infosys Limited, Ford Motor Company and Public Storage

by Zacks Equity Research

The Zacks Analyst Blog Highlights AbbVie, The Boeing Company, Infosys Limited, Ford Motor Company and Public Storage are included in this analyst blog.

Sheraz Mian headshot

Top Analyst Reports for AbbVie, Boeing & Infosys

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including AbbVie Inc. (ABBV), The Boeing Company (BA), and Infosys Limited (INFY).

Zacks Equity Research

Amgen (AMGN) Provides Strong Long-Term Outlook, Shares Up

by Zacks Equity Research

Amgen (AMGN) outlines a strategy to grow its business through the end of this decade on the back of strong demand for existing products and potential of novel pipeline candidates targeting diverse indications.

Zacks Equity Research

The Zacks Analyst Blog Highlights: AbbVie, Merck, Eli Lilly, Novartis and Pfizer

by Zacks Equity Research

AbbVie, Merck, Eli Lilly, Novartis and Pfizer are included in this analyst blog.

Zacks Equity Research

Viatris (VTRS) Gets FDA Nod for Generic Drug in Dry Eye Disease

by Zacks Equity Research

Viatris' (VTRS) subsidiary is the first to receive approval from the FDA to market a generic version of AbbVie's Restasis for the treatment of dry eye disease.

Kinjel Shah headshot

Pharma Stock Roundup: MRK, LLY, ABBV Post Q4 Earnings, PFE Ends Vupanorsen Program

by Kinjel Shah

AbbVie (ABBV), Merck (MRK), Eli Lilly (LLY) and Novartis (NVS) report fourth-quarter results. Pfizer (PFE) ends vupanorsen development.

Zacks Equity Research

AbbVie's (ABBV) Q4 Earnings Surpass Estimates, Sales Miss

by Zacks Equity Research

AbbVie (ABBV) beats fourth-quarter 2021 earnings estimates while missing the same for sales. Strong demand for immunology drugs, aesthetics and cosmetics drives sales. Shares up.

Zacks Equity Research

AbbVie (ABBV) Tops Q4 Earnings Estimates

by Zacks Equity Research

AbbVie (ABBV) delivered earnings and revenue surprises of 0.61% and 0.94%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Indrajit Bandyopadhyay headshot

Pharma Stocks to Report Q4 Earnings on Feb 2: ABBV, NVS & NVO

by Indrajit Bandyopadhyay

Let us take a look at three large pharma companies - ABBV, NVS and NVO - due to release their quarterly results on Feb 2.

Zacks Equity Research

Why AbbVie (ABBV) Might Surprise This Earnings Season

by Zacks Equity Research

AbbVie (ABBV) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Daniel Laboe headshot

Buyers Come In With A Penchant For Growth After Short Market Correction

by Daniel Laboe

This week's riveting earnings line-up promises to be chalked full of enlightening quarterly reports from leading corporations across sectors

Zacks Equity Research

Bristol-Myers (BMY) to Post Q4 Earnings: What's in Store?

by Zacks Equity Research

Bristol-Myers' (BMY) Q4 earnings might have gained from strong demand for its multiple myeloma drug, Revlimid. Operating expenses might have jumped on costs associated with the broader portfolio.

Zacks Equity Research

Lilly (LLY) Stops Lupus Study, Expects CRL for Olumiant in Eczema

by Zacks Equity Research

While Eli Lilly (LLY) and Incyte (INCY) have decided to discontinue the development of JAK inhibitor Olumiant in lupus indication, they expect a complete response letter from the FDA for Olumiant in atopic dermatitis.

Zacks Equity Research

AbbVie's (ABBV) Q4 Earnings May Reflect Slower Sales Recovery

by Zacks Equity Research

AbbVie's (ABBV) drugs are expected to have continued the recovering trend in sales during the fourth quarter. However, increased COVID-19 cases are likely to have hurt the pace of recovery during the quarter.

Zacks Equity Research

Zacks Investment Ideas feature highlights: Bank of America, AbbVie, and Microsoft

by Zacks Equity Research

Bank of America, AbbVie, and Microsoft are highlighted in this Investment Ideas article.